Altana AG

ots Ad hoc-Service: Altana AG

Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. -----------------------------------------------------

    Bad Homburg (ots Ad hoc-Service) -      The U.S. Food and Drug
Administration (FDA) has approved the intravenous (i.v.) formulation
of the gastrointestinal drug Pantoprazole for the USA. This makes
Pantoprazole the first proton pump inhibitor (PPI) in the USA to be
approved for both formulations tablet and i.v. Final release of the
product by ALTANAs sales partner American Home Products (AHP) is
scheduled for April.

    Since May 2000, Pantoprazole has been marketed in the USA via AHP as 40 mg tablets under the product name PROTONIX. The drug is used to treat acid-related esophageal conditions. The intravenous form of the product, PROTONIX I.V., is used for short-term (seven to ten days) treatment of gastroesophageal reflux disease (GERD) a condition caused by the reflux (reverse flow) of stomach acid into the esophagus. The i.v. formulation that has now been approved is an important therapeutic aid in the treatment of all patients who are unable to take PROTONIX in tablet form.

WKN: 760080; Index: MDAX Listed: Amtlicher Handel in Frankfurt, Düsseldorf und Berlin; Freiverkehr in Bremen, Hamburg, Hannover, München und Stuttgart

End ----------------------------------------------------- Internet:

Original-Content von: Altana AG, übermittelt durch news aktuell

Weitere Meldungen: Altana AG

Das könnte Sie auch interessieren: